Compare Nuwellis Inc (NUWE) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Unilever plc — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Unilever plc trades at $61.66 (market cap $131.63B). The key difference: Unilever plc is far larger — about 59831.8× Nuwellis Inc's market cap, and Unilever plc pays a 3.43% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Unilever plc for 112 Days on average.
| NUWE | UL | |
|---|---|---|
Market Cap | $2.20M | $131.63B |
Volume | 121,544 | 2,978,741 |
Sector | Health | Consumer Staples |
52-Week High | $146.65 | $74.59 |
52-Week Low | $0.68 | $55.05 |
Typical Hold Time | 26 Days | 112 Days |
Enterprise Value | -$1.52M | $156.65B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Unilever (UL) trades at $60.98, up 0.3% on the day, amid a bearish technical signal and mixed earnings performance. The company reported Q2 2026 EPS of $1.83, narrowly missing the $1.84 estimate, continuing a trend of recent misses. Financially, UL maintains strong profitability with an 18.32% net income margin and 54.56% ROE, though revenue declined to $50.5B in 2025. Analyst sentiment is divided with a Hold consensus, while news highlights strategic shifts including the planned food business merger with McCormick.
The outlook balances high profitability and emerging market exposure against execution risks from portfolio restructuring and recent earnings misses. The stock's valuation at a P/E of 21.32 appears reasonable relative to historical margins, but investor caution is warranted given the bearish technical trend and regulatory scrutiny of the McCormick deal. Upside potential hinges on successful integration and volume growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
